Malecare has been an active and early member of the Defense Health Research Consortium. The consortium currently consists of 47 different organizations, which educate and advocate for research Department of Defense funding for multiple different diseases and syndromes. The consortium’s goal is to lobby Congress to continue to and to expand support for the Department [...]
Traditionally, the FDA makes its regulatory decisions based solely on demonstrated safety and provable increases in meaningful survival data. The FDA asks, Will a new treatment that is being considered for approval be able to extend our life longer than the current standard of care? They also ask if it will extend our life is [...]
Doctors are not trained to communicate with patients. Now, with the onset of electronic medical records this problem has become worse. Many of them hardly even look their patient in the eyes; instead their faces are often buried in the computer screen and not on us. Since they don’t really know us, they stumble around, [...]
It is important that survivors keep up on the professional standards of our doctors to make sure that we receive the best care and the most current care. It is easy for doctors to just do it the way they were first trained, even if their training was twentyor thirty years ago. Recent news includes [...]
After a great deal of confusion and what turned out to be an error on my part I wish to let you know that the NICE (The U.K.’s National Institute for Health and Care Excellence) Guidance I shared on the blog on January 28, 2014 (http://advancedprostatecancer.net/?p=4360 ) about enzalutamide (Xtandi) was not accurate. In my [...]